Trial Information

Summary: Phase II Study of Dasatinib (BMS-354825) for Androgen - Deprived Progressive Prostate Cancer

The purpose of this study is to learn if men with metastatic and rising Prostate Specific Antigen (PSA), who have been surgically castrated or are undergoing androgen deprivation with Luteinizing Hormone Releasing (LHRH) treatment, respond to Dasatinib. The safety of this treatment will also be studied.

Inclusion Criteria

• Males, 18 or older
• Proven advanced prostate cancer
• Documented metastatic disease
• Rising PSA levels
• Castrate levels of testosterone

Exclusion Criteria

• Symptomatic CNS (brain or spinal cord) metastasis
• Medical condition which may increase risk of toxicity
• Any prior or ongoing anti-cancer medical therapy or immunotherapy for prostate cancer other then primary androgen deprivation agents
• Unable to take oral medication

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:32:20 AM